Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 203 participants.

Also called NCT03829657

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
Theravance Biopharma (from the registry)
Registry
  • NCT NCT03829657
  • EudraCT 2018-003941-41
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Bulgaria, Canada, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Portugal, Russia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03829657. Randomized; triple masking; primary purpose treatment. Start 2019-02-22 (actual); primary completion 2021-11-10 (actual). Results posted on 2023-01-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Acronym
REDWOOD
Condition
Symptomatic Neurogenic Orthostatic Hypotension
Condition
MSA
Condition
Parkinson's Disease (PD)
Condition
Pure Autonomic Failure (PAF)
Intervention (Drug)
ampreloxetine
Intervention (Drug)
Placebo
Lead sponsor
Theravance Biopharma (class: industry)

Record details

Record id
cardio:ct-nct03829657
Content hash
c96c917d7b632935061158ad2e4d8cf2f9da925a2042cdb9f5d259628fc358de